▎What is TB-500?
TB-500 (Thymosin Beta-4) is an endogenous peptide composed of 43 amino acids, derived from the core active region of naturally occurring human thymosin β4. It exhibits excellent water solubility and structural stability, naturally occurring widely in tissues like blood, muscle, and skin, and can be obtained through synthetic methods. Compared to intact thymosin β4, TB-500 retains key biological activity while being more readily absorbed by tissues via injection. It functions without requiring complex modifications, making it one of the most extensively studied peptide molecules in the field of tissue repair.
TB-500 promotes cell migration and tissue regeneration by activating the migratory capacity of repair-related cells such as endothelial cells and fibroblasts. It accelerates angiogenesis and collagen deposition, aiding in the repair of connective tissue injuries in muscles, tendons, ligaments, and skin. Simultaneously, it regulates extracellular matrix balance to reduce excessive scar formation. It exhibits anti-inflammatory and cytoprotective effects by inhibiting the release of pro-inflammatory factors like TNF-α and IL-1β, thereby reducing tissue inflammation and edema. Furthermore, it enhances cellular antioxidant stress resistance, mitigating damage from ischemia and toxins, and plays a crucial role in stabilizing the microenvironment of injured tissues.
It is used as an adjunct therapy for sports-related injuries such as muscle strains, tendinitis, and ligament tears, shortening the healing cycle and aiding in the restoration of athletic function. In wound healing, it accelerates closure of chronic non-healing wounds (e.g., diabetic foot ulcers) and burn injuries by promoting granulation tissue growth and epithelial cell migration. In tissue damage interventions, it also demonstrates efficacy in nerve injury (e.g., peripheral nerve contusion) and post-myocardial ischemia repair studies.
Conclusion
The BPC-157/TB-500 Blend is a composite system comprising two endogenous peptides with tissue repair activity. BPC-157, derived from human gastric mucosal protein, contains 15 amino acids, while TB-500 is an active fragment of thymosin β4, comprising 43 amino acids. When combined, they exert synergistic effects. BPC-157 promotes fibroblast proliferation, enhances mucosal barrier integrity, and suppresses pro-inflammatory factor release, while TB-500 regulates actin polymerization, accelerates cell migration, and stimulates angiogenesis. Together, they enhance tissue regeneration and repair efficiency, with additional anti-inflammatory effects, visceral organ protection, and improvement of the cellular microenvironment. Current application research focuses on sports injury recovery (e.g., tendinitis, muscle strains, ligament injuries); gastrointestinal mucosal protection (e.g., gastric ulcer, inflammatory bowel disease adjunctive intervention); and multi-tissue damage synergistic restoration (e.g., skin wounds, minor visceral injuries). This complementary mechanism shortens repair cycles, reduces inflammatory responses, and facilitates intervention in tissue damage-related issues.
About The Author
The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
